Treating Bipolar Depression Depends on Evidence, Judgment
October 6, 2011|Psychiatry
Author and Disclosure Information
EXPERT ANALYSIS FROM THE ANNUAL CONGRESS OF THE EUROPEAN COLLEGE OF NEURO-
PSYCHOPHARMACOLOGY
Dr. Nierenberg said he has a patent pending on combined treatment of mood disorders with buspirone, bupropion, and melatonin, and he co-owns a copyright on a structured clinical interview for the Montgomery-Åsberg Depression Rating Scale. He said he has received honoraria from Eli Lilly, AstraZeneca, Forest, and Janssen, and that he has received research grants from Pam Labs, Pfizer, and Shire.
